ClinicalTrials.gg
RecruitingNCT05745285Updated Oct 16, 2026

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

An interventional study of LLS Program in Leukemia, Lymphoma and Myeloma, sponsored by University of Miami. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Miami · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,668 studies in Leukemia with a site in United States — 113 open to participants now, 181 under way, 11 of them phase 3. Leukemia · United States.

Planned enrollment
53rd of 1,350
400 · median 35
Started
2025
with 23 others
No phase
147 of 1,668
20 open now
Primary completion
2026-11
later than 47 of 178 live
Registered
1,577th of 1,668
by date

Among the 1,668 studies in Leukemia with a site in United States, this one is the 53rd largest by planned enrollment of the 1,350 interventional ones that give a count, is one of 24 that started in 2025, is one of 147 with no phase, reaches primary completion later than 47 of the 178 other live ones, and was the 1,577th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.

Browse Leukemia studies →

Open to participants now

113 of the 1,668 studies in Leukemia with a site in United States are open now. Recruiting first, the newest first:

108 more — sign in →

All 113 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,668 studies in Leukemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.

03

Conditions studied

  • Leukemia
  • Lymphoma
  • Myeloma
  • Myelodysplastic Syndromes
  • Myeloproliferative Neoplasm

Keywords

  • Blood cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN).
  • Have received, be receiving, or be planning to receive primary or relapse treatment for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) and meet at least one of the following criteria:

    • Be currently receiving treatment which started within the past 18 months OR
    • Be planning to start treatment within one month OR
    • Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.
  • Not be currently participating in any LLS programs or services
  • Be willing to be followed for 6 months
  • Speak English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Are not diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)
  • Do not meet at least one of the following criteria if treated or planning to get treated for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN):

    • Be currently receiving treatment which started within the past 18 months OR
    • Be planning to start treatment within one month OR
    • Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days.
  • Are currently participating in any LLS programs or services
  • Are not willing to be followed for 6 months
  • Do not speak English or Spanish.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    LLS Program and Usual Care Group

    Participants in the LLS Program and Usual Care condition will receive LLS services such as information, services, and financial aid so that patients can have better access to healthcare and better quality of life. Participants will also receive the standard care. Participants will be in this group for 6 months.

    Other: LLS Program

  • No intervention
    Usual Care Group

    Participants will receive the standard care. Participants will be in this group for 6 months.

Interventions

  • OtherLLS Program

    The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.

06

What researchers measure

Primary outcomes

  1. Change in number of care needs as measured by the Access to Care Survey

    Change in number of care needs will be assessed via the self-report Access to Care Survey which includes access to primary and specialty care, access to medications specific to cancer care, and access to financial resources specific to cancer care. The survey uses a composite score to assess participants' needs. Scores range from 0 to 21 with lower scores indicating better access to care needs.

    Time frame: Baseline, 3 month, 6 month

  2. Change in number of medication access problems as measured by the Access to Care Survey

    Change in number of medication use will be assessed via the self-report Access to Care Survey which includes access to medications specific to cancer care. The survey uses a composite score to assess participants' medication use. Scores range from 0 to 6 with lower scores indicating better access to medication.

    Time frame: Baseline, 3 month, 6 month

Secondary outcomes

  1. Change in general health-related quality of life (HRQL)

    The Functional Assessment of Cancer Therapy-General (FACTG) 5 will be administered to evaluate general domains of HRQL. Quality of life is scored on a scale with scores ranging from 0 to 108, with higher scores indicating better health-related quality of life outcomes.

    Time frame: Baseline, 3 month, 6 month

  2. Change in treatment satisfaction as measured by FACIT

    The 8-item Functional Assessment of Chronic Illness Therapy (FACIT) Treatment Satisfaction - General (TS-G) is a Likert scale designed to assess satisfaction with general medical treatments. A summary score yields a treatment satisfaction composite with higher scores indicating greater treatment satisfaction.

    Time frame: Baseline, 3 month, 6 month

  3. Change in financial toxicity as measured by FACIT-COST

    The 12-item Functional Assessment of Chronic Illness Therapy - Comprehensive Score for Financial Toxicity (FACIT-COST) is a patient reported outcome measure that describes the financial distress experienced by cancer patients. Score range 0-44 with higher scores indicating better Financial Well-Being.

    Time frame: Baseline, 3 month, 6 month

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.

Of 103 non-industry interventional studies with no phase under Leukemia, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 128. This study's planned 21 months is below that.

Counting every sponsor, half of 110 studies reached it within 38 months; a quarter within 22 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2026 → Nov 2026 and completion Nov 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartActual
Feb 4, 2025
Primary completionEst.
Nov 30, 2026was Oct 2026
CompletionEst.
Jul 1, 2027was Nov 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Nov 30, 2026
Oct 16, 2026
Study completion
Nov 1, 2026→Jul 1, 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Oct 31, 2026→Nov 30, 2026
    Study completion Nov 1, 2026→Jul 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05745285
Collaborators
Blood Cancer United
Responsible party
Frank Penedo (Professor, University of Miami) — Principal investigator
First posted
Feb 27, 2023
Start date
Feb 4, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Carlos Melara, MD
Contact
cam32407@med.miami.edu
3052438300
Sara Fleszar-Pavlovic, PhD
Contact
sarafleszarpavlovic@med.miami.edu
Frank Penedo, PhD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion